Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shen-Fu injection for cardiogenic shock in acute decompensated heart failure
ChiCTR1900026086Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of shenfu injection in heart failure (HF) and cardiogenic shock (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Incidence of composite cardiovascular end-point events at 28 and 90 days. Started Oct 2019; status: recruiting.
02
Drugs
shenfu injection
03
Conditions
heart failure (HF)cardiogenic shock
Beyond the preview
Go deeper on ChiCTR1900026086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026086.